acalabrutinib (calquence) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Acalabrutinib, also known as ACP-196, is a novel irreversible second-generation Bruton’s tyrosine kinase (BTK) inhibitor, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and that, was rationally designed to be more potent and selective than ibrutinib. This drug in clinical trials phase III for treatment the treatment of relapsed chronic lymphocytic leukemia. Also in combination with others drugs, Acalabrutinib in phase II of clinical trials for the treatment Glioblastoma Multiforme, Mantle Cell Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Rheumatoid Arthritis and some others.   NCATS

Chemistry

  • SMILES: CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=NC=CC=C5
  • InChIKey: WDENQIQQYWYTPO-IBGZPJMESA-N
  • Mol. Mass: 465.5065
  • ALogP: 3.31
  • ChEMBL Molecule:
    acalabrutinib  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$112.3061

United States

$174.2045 - $212.0202
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

acalabrutinib | acp-196

Organizations (61)

Research & Development (61)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (49)

Approved Indications (1)


 

Lymphoma, Mantle-Cell

Experimental Indications - Clinical Trial Phases 1-4 (49)


 

Allergy and Immunology (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 2)

Antigens, CD (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Biological Availability (Phase 1)

Biomarkers (Phase 2)

Burkitt Lymphoma (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Communicable Diseases (Phase 1)

COVID-19 (Phase 3)

Cyclin D1 (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Food Hypersensitivity (Phase 2)

Glioblastoma (Phase 2)

Graft vs Host Disease (Phase 2)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

Hodgkin Disease (Phase 1/Phase 2)

Immunoglobulin M (Phase 2)

Leukemia (Phase 1/Phase 2)

Leukemia, B-Cell (Phase 1/Phase 2)

Leukemia, Hairy Cell (Phase 1/Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 2)

Leukemia, Prolymphocytic (Phase 1/Phase 2)

Liver Diseases (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1/Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell ()

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Lymphoproliferative Disorders (Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Neoplasms (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Pharmacokinetics (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Therapeutic Equivalency (Phase 1)

Translocation, Genetic (Phase 2)

Transplantation (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 115
  • # of Trial Organizations: 61

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue